重症患者腹内高压监测与管理专家共识(2020版)

2020-10-30 中华消化外科杂志.2020.19(10):1030-1037.

腹内高压在重症患者中并不鲜见,文献报道在ICU 中其发生率可达30%~40% 。腹内高压可引起器官组织低灌注,甚至发展至腹腔间隔室综合征(ACS),导致出现多器官和系统功能障碍,给救治带来很大挑战。2

中文标题:

重症患者腹内高压监测与管理专家共识(2020版)

发布机构:

发布日期:

2020-10-30

简要介绍:

腹内高压在重症患者中并不鲜见,文献报道在ICU 中其发生率可达30%~40% 。腹内高压可引起器官组织低灌注,甚至发展至腹腔间隔室综合征(ACS),导致出现多器官和系统功能障碍,给救治带来很大挑战。2007 年世界腹腔间隔室协会(WSACS)发布关于腹内高压和ACS 的诊断与治疗指南,并于2013 年及2017 年分别更新了指南内容,受到广泛关注。然而该指南对ICU 重症患者的管理,没有充分和确切的推荐意见。为此,中国腹腔重症协作组结合大量循证医学证据和病理生理研究,针对重症患者腹内高压监测与管理中受到关注的18 个问题给出相关建议。

下载附件:

(因为版权问题,不支持下载)

评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1053001, encodeId=5ab51053001ea, content=非常好,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2d5611116, createdName=ms4000001710844140, createdTime=Sun Sep 19 12:07:44 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005237, encodeId=a5fa100523ee4, content=不错,有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201124/3358f7f03c3a4606bb12320c59e5f3e7/48f5adbd4bc94d4599ae14099014247a.jpg, createdBy=c44e1981245, createdName=1e183001m12(暂无匿称), createdTime=Wed Aug 04 23:07:30 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000330, encodeId=d2cf100033090, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fbc5483634, createdName=ms9000000692474617, createdTime=Sat Jul 17 10:30:43 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998508, encodeId=767599850863, content=厉害,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5yPjicnk1hIC8tyaftMZXMliclLEBZ6JSibibuqejqvUHoj9icdUicmSK8ujoGP8bFb2wMQhp5tInEx1sC27vXFgYN2Q/132, createdBy=778a5199321, createdName=艾雯, createdTime=Sun Jul 11 16:04:36 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996375, encodeId=6f479963e53a, content=厉害,很解惑, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG581169279CC6F1507.jpg, createdBy=1a721365208, createdName=Zouzijun301, createdTime=Mon Jul 05 12:29:00 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-09-19 ms4000001710844140

    非常好,很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1053001, encodeId=5ab51053001ea, content=非常好,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2d5611116, createdName=ms4000001710844140, createdTime=Sun Sep 19 12:07:44 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005237, encodeId=a5fa100523ee4, content=不错,有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201124/3358f7f03c3a4606bb12320c59e5f3e7/48f5adbd4bc94d4599ae14099014247a.jpg, createdBy=c44e1981245, createdName=1e183001m12(暂无匿称), createdTime=Wed Aug 04 23:07:30 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000330, encodeId=d2cf100033090, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fbc5483634, createdName=ms9000000692474617, createdTime=Sat Jul 17 10:30:43 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998508, encodeId=767599850863, content=厉害,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5yPjicnk1hIC8tyaftMZXMliclLEBZ6JSibibuqejqvUHoj9icdUicmSK8ujoGP8bFb2wMQhp5tInEx1sC27vXFgYN2Q/132, createdBy=778a5199321, createdName=艾雯, createdTime=Sun Jul 11 16:04:36 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996375, encodeId=6f479963e53a, content=厉害,很解惑, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG581169279CC6F1507.jpg, createdBy=1a721365208, createdName=Zouzijun301, createdTime=Mon Jul 05 12:29:00 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-08-04 1e183001m12(暂无匿称)

    不错,有意义

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1053001, encodeId=5ab51053001ea, content=非常好,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2d5611116, createdName=ms4000001710844140, createdTime=Sun Sep 19 12:07:44 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005237, encodeId=a5fa100523ee4, content=不错,有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201124/3358f7f03c3a4606bb12320c59e5f3e7/48f5adbd4bc94d4599ae14099014247a.jpg, createdBy=c44e1981245, createdName=1e183001m12(暂无匿称), createdTime=Wed Aug 04 23:07:30 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000330, encodeId=d2cf100033090, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fbc5483634, createdName=ms9000000692474617, createdTime=Sat Jul 17 10:30:43 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998508, encodeId=767599850863, content=厉害,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5yPjicnk1hIC8tyaftMZXMliclLEBZ6JSibibuqejqvUHoj9icdUicmSK8ujoGP8bFb2wMQhp5tInEx1sC27vXFgYN2Q/132, createdBy=778a5199321, createdName=艾雯, createdTime=Sun Jul 11 16:04:36 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996375, encodeId=6f479963e53a, content=厉害,很解惑, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG581169279CC6F1507.jpg, createdBy=1a721365208, createdName=Zouzijun301, createdTime=Mon Jul 05 12:29:00 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-17 ms9000000692474617

    想看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1053001, encodeId=5ab51053001ea, content=非常好,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2d5611116, createdName=ms4000001710844140, createdTime=Sun Sep 19 12:07:44 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005237, encodeId=a5fa100523ee4, content=不错,有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201124/3358f7f03c3a4606bb12320c59e5f3e7/48f5adbd4bc94d4599ae14099014247a.jpg, createdBy=c44e1981245, createdName=1e183001m12(暂无匿称), createdTime=Wed Aug 04 23:07:30 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000330, encodeId=d2cf100033090, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fbc5483634, createdName=ms9000000692474617, createdTime=Sat Jul 17 10:30:43 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998508, encodeId=767599850863, content=厉害,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5yPjicnk1hIC8tyaftMZXMliclLEBZ6JSibibuqejqvUHoj9icdUicmSK8ujoGP8bFb2wMQhp5tInEx1sC27vXFgYN2Q/132, createdBy=778a5199321, createdName=艾雯, createdTime=Sun Jul 11 16:04:36 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996375, encodeId=6f479963e53a, content=厉害,很解惑, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG581169279CC6F1507.jpg, createdBy=1a721365208, createdName=Zouzijun301, createdTime=Mon Jul 05 12:29:00 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-11 艾雯

    厉害,谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1053001, encodeId=5ab51053001ea, content=非常好,很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2d5611116, createdName=ms4000001710844140, createdTime=Sun Sep 19 12:07:44 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005237, encodeId=a5fa100523ee4, content=不错,有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201124/3358f7f03c3a4606bb12320c59e5f3e7/48f5adbd4bc94d4599ae14099014247a.jpg, createdBy=c44e1981245, createdName=1e183001m12(暂无匿称), createdTime=Wed Aug 04 23:07:30 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000330, encodeId=d2cf100033090, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fbc5483634, createdName=ms9000000692474617, createdTime=Sat Jul 17 10:30:43 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998508, encodeId=767599850863, content=厉害,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5yPjicnk1hIC8tyaftMZXMliclLEBZ6JSibibuqejqvUHoj9icdUicmSK8ujoGP8bFb2wMQhp5tInEx1sC27vXFgYN2Q/132, createdBy=778a5199321, createdName=艾雯, createdTime=Sun Jul 11 16:04:36 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996375, encodeId=6f479963e53a, content=厉害,很解惑, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161027/IMG581169279CC6F1507.jpg, createdBy=1a721365208, createdName=Zouzijun301, createdTime=Mon Jul 05 12:29:00 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-05 Zouzijun301

    厉害,很解惑

    0

拓展阅读

中国神经外科重症患者气道管理专家共识(2016)

中华医学会神经外科学分会 · 2016-06-07

中国神经外科重症患者消化与营养管理专家共识(2016)

中华医学会神经外科学分会 · 2016-06-07

中国神经外科重症患者感染诊治专家共识(2017)

中华医学会神经外科学分会 · 2017-06-06

2018 ESICM第二共识:重症患者舌下微循环的评估

欧洲危重病医学会(ESICM,European Society of Intensive Care Medicine) · 2018-02-06

2018 DAS/ICS/FICM/RCoA指南:重症患者气管插管管理

困难气道协会(DAS,Difficult Airway Society) · 2018-02-01

2018 共识声明:亚太和中东地区重症患者的营养治疗

国外急诊科相关专家小组(统称) · 2018-04-02